| Malignant neoplasm of breast
Kisqali vs Aromasin
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Kisqali vs Aromasin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAromasin has a higher rate of injection site reactions vs Kisqali based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Aromasin but not Kisqali, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kisqali
Aromasin
At A Glance
Oral
Once daily (21/28-day cycle)
CDK4/6 inhibitor
Oral
Daily
Aromatase inactivator
Indications
- Malignant neoplasm of breast
- Advanced breast cancer
- Malignant neoplasm of breast
- Advanced breast cancer
Dosing
Malignant neoplasm of breast 400 mg (two 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with an aromatase inhibitor, for 3 years or until disease recurrence or unacceptable toxicity.
Advanced breast cancer 600 mg (three 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with fulvestrant or an aromatase inhibitor.
Malignant neoplasm of breast, Advanced breast cancer 25 mg orally once daily after a meal; increase to 50 mg once daily after a meal when administered with a strong CYP 3A4 inducer.
Contraindications
—
- Known hypersensitivity to exemestane or any excipient
Adverse Reactions
Most common (>=20%) Neutrophils decreased, leukocytes decreased, lymphocytes decreased, hemoglobin decreased, ALT increased, AST increased, infections, nausea, fatigue, headache, creatinine increased, platelets decreased, diarrhea, vomiting, alopecia, cough, rash, back pain
Serious Interstitial lung disease/pneumonitis, severe cutaneous adverse reactions (SJS, TEN), QT interval prolongation, hepatotoxicity, neutropenia
Postmarketing Interstitial lung disease/pneumonitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/DRESS
Most common (>=10%) Hot flushes, fatigue, arthralgia, headache, insomnia, increased sweating
Serious Cardiac ischemic events (myocardial infarction, angina, myocardial ischemia), cardiac failure, clinical fractures
Postmarketing Hypersensitivity, hepatitis including cholestatic hepatitis, paresthesia, tendon disorders including tendon rupture and tendonitis and tenosynovitis, acute generalized exanthematous pustulosis, urticaria, pruritus
Pharmacology
Ribociclib is a CDK4/6 inhibitor that blocks cyclin D-CDK4/6-mediated phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle in the G1 phase and reducing proliferation in breast cancer models; in combination with antiestrogen therapy (letrozole or fulvestrant), it produces greater tumor growth inhibition than either agent alone.
Aromatase inactivator; exemestane is an irreversible steroidal aromatase inactivator that acts as a false substrate for the aromatase enzyme, binding irreversibly to the active site ('suicide inhibition') and significantly lowering circulating estrogen concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone biosynthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kisqali
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Aromasin
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Kisqali
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Aromasin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Kisqali
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Aromasin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Novartis Oncology Universal Co-pay Program: KisqaliCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Aromasin Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KisqaliView full Kisqali profile
AromasinView full Aromasin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.